why choose us

First received: August 10, 2022

Clinical Trial: Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma.

Study Status: Completed

Recruit Status: RECRUITING

Condition: Renal Cell Carcinoma

Study Type: INTERVENTIONAL


Official Title: Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma.

Brief Summary: To learn if the combination of ciforadenant, ipilimumab, and nivolumab can help to control advanced renal cell carcinoma

Read more